Collplant Biotechnologies Ltd ADR (CLGN) Stock Price, Quote & News

Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; VergenixSTR, a soft tissue matri...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 73 232 5600

Fax: 972 73 232 5602

Website: collplant.com

Address:

Weizmann Science Park, 4 Oppenheimer P.O. Box 4132, Rehovot, Israel

prismmarketview Nov. 28 at 3:10 PM

CollPlant $CLGN updates Q3 results, strengthening its cash runway and expanding U.S. infrastructure as its aesthetics and BioInk programs move forward. https://prismmarketview.com/collplant-strengthens-cash-runway-and-expands-u-s-infrastructure-as-aesthetics-and-bioink-pipeline-advances/

0 · Reply

DARKP00L Nov. 28 at 2:28 PM

$CLGN 09:06 on Nov. 28 2025 D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target #tradeideas

0 · Reply

JarvisFlow Nov. 28 at 2:06 PM

D. Boral Capital updates rating for CollPlant Biotechnologies ( $CLGN ) to Buy, target set at 12.

0 · Reply

mikesterz7 Nov. 26 at 4:23 PM

$CLGN The firm reported revenue of $77,000 for the three months ended September, above the $4,000 reported in the corresponding quarter of 2024, but below an analyst estimate of $5.03 million, according to data from Fiscal AI.

0 · Reply

StocktwitsNews Nov. 26 at 3:52 PM

CLGN Stock Crashed 14% Today – Disappointing Earnings, Workforce Reduction Plan Draws Investor Attention $CLGN https://stocktwits.com/news/equity/markets/clgn-stock-crashes-disappointing-earnings-workforce-reduction-plan-draws-investor-attention/cL53AMUREWV

0 · Reply

JarvisFlow Oct. 20 at 1:27 PM

D. Boral Capital updates rating for CollPlant Biotechnologies ( $CLGN ) to Buy, target set at 12.

0 · Reply

Tom678 Oct. 20 at 11:15 AM

$CLGN another good news

0 · Reply

Johfad54 Oct. 17 at 12:00 PM

$CLGN Someone buy this pls, need to sell

0 · Reply

Tom678 Oct. 16 at 11:24 AM

$CLGN amazing news , buying here

0 · Reply

Johfad54 Oct. 16 at 11:10 AM

$CLGN How is there only 2 people here lol

0 · Reply

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Nov 18, 2025, 7:00 AM EST - 19 days ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2025 THIRD QUARTER FINANCIAL RESULTS

Oct 27, 2025, 7:01 AM EDT - 5 weeks ago

CollPlant Expands its rhCollagen Distribution Capabilities in the United States and Canada

Oct 20, 2025, 7:00 AM EDT - 6 weeks ago

CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

Oct 16, 2025, 7:00 AM EDT - 7 weeks ago

First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

Sep 30, 2025, 7:00 AM EDT - 2 months ago

CollPlant Biotechnologies Announces Positive Results from non-clinical Studies of its Photocurable Regenerative Dermal and Soft Tissue Filler

Sep 15, 2025, 7:00 AM EDT - 2 months ago

CollPlant Expands the Distribution of its VergenixSTR Product in Europe

Sep 2, 2025, 7:00 AM EDT - 3 months ago

CollPlant to Present at the 2025 International Conference on Biofabrication

Aug 25, 2025, 7:00 AM EDT - 3 months ago

CollPlant to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 7:00 AM EDT - 3 months ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Aug 5, 2025, 7:00 AM EDT - 4 months ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR SECOND QUARTER FINANCIAL RESULTS

Jul 14, 2025, 7:00 AM EDT - 5 months ago

CollPlant Appoints Collagen Biomaterials Expert as New Head of North America Commercial Operations

Jun 9, 2025, 7:00 AM EDT - 6 months ago

COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL TECHNOLOGIES

Jun 4, 2025, 7:00 AM EDT - 6 months ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES EUROPEAN PATENT ALLOWANCE SECURED FOR ITS COLLAGEN-BASED FORMULATIONS USABLE AS SOFT TISSUE FILLERS AND IMPLANTS

May 30, 2025, 7:00 AM EDT - 6 months ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES $3.6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

May 28, 2025, 7:00 AM EDT - 6 months ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

May 14, 2025, 7:00 AM EDT - 7 months ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FIRST QUARTER FINANCIAL RESULTS

Apr 15, 2025, 8:00 AM EDT - 8 months ago

CollPlant's Collink.3D® BioInks and Technologies Offer a Relevant and Timely Solution to FDA's Plan to Reduce Animal Testing in Preclinical Safety Studies

Mar 26, 2025, 7:58 PM EDT - 9 months ago

CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript

Mar 26, 2025, 8:00 AM EDT - 9 months ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

SSYS

Mar 19, 2025, 7:00 AM EDT - 9 months ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Feb 24, 2025, 7:00 AM EST - 10 months ago

CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia

Feb 12, 2025, 6:00 AM EST - 10 months ago

CollPlant Biotechnologies Provides a Corporate Update

Nov 27, 2024, 11:36 AM EST - 1 year ago

CollPlant Biotechnologies Ltd (CLGN) Q3 2024 Earnings Call Transcript

Nov 27, 2024, 7:00 AM EST - 1 year ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

SSYS

Nov 12, 2024, 7:00 AM EST - 1 year ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Aug 20, 2024, 6:59 PM EDT - 1 year ago

CollPlant Biotechnologies Ltd. (CLGN) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 7:00 AM EDT - 1 year ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2024 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

SSYS

Aug 19, 2024, 8:30 AM EDT - 1 year ago

CollPlant and Stratasys Announce Pre-clinical Study for Regenerative Commercial-Sized Breast Implants

SSYS

Aug 6, 2024, 7:00 AM EDT - 1 year ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 SECOND QUARTER FINANCIAL STATEMENTS AND CONFERENCE CALL INFORMATION

Jul 29, 2024, 7:00 AM EDT - 1 year ago

CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report

Jun 6, 2024, 7:00 AM EDT - 1 year ago

CollPlant Successfully Bio-Prints 200cc Commercial-Size Regenerative Breast Implants and Reports Additional Positive Pre-Clinical Data

May 29, 2024, 12:02 PM EDT - 1 year ago

CollPlant Biotechnologies Ltd. (CLGN) Q1 2024 Earnings Call Transcript

May 29, 2024, 7:00 AM EDT - 1 year ago

CollPlant Biotechnologies Announces First Quarter Financial Results For 2024 and Provides Corporate Update

May 16, 2024, 7:00 AM EDT - 1 year ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Apr 4, 2024, 1:15 PM EDT - 1 year ago

CollPlant Biotechnologies Ltd. (CLGN) Q4 2023 Earnings Call Transcript

Apr 4, 2024, 7:17 AM EDT - 1 year ago

COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 26, 2024, 8:00 AM EDT - 1 year ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 FULL YEAR FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Feb 15, 2024, 8:00 AM EST - 1 year ago

CollPlant Issues Letter to Shareholders

Jan 8, 2024, 7:18 AM EST - 2 years ago

CollPlant's CEO to Present at the Octane Aesthetic Tech Forum Conference, in Newport Beach, California

Jan 2, 2024, 7:00 AM EST - 2 years ago

CollPlant Biotechnologies Begins Preclinical Trial with Commercial-Size, Regenerative Breast Implants

Nov 29, 2023, 2:21 PM EST - 2 years ago

CollPlant Biotechnologies Ltd. (CLGN) Q3 2023 Earnings Call Transcript

Nov 29, 2023, 7:00 AM EST - 2 years ago

CollPlant Biotechnologies Announces Third Quarter Financial Results for 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 THIRD QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

Nov 1, 2023, 7:05 AM EDT - 2 years ago

CollPlant Biotechnologies Announces Patent Granted in U.S. for Photocurable Dermal Filler

Sep 21, 2023, 7:00 AM EDT - 2 years ago

CollPlant Biotechnologies Joins the United Nations Global Compact, The World's Largest Corporate Sustainability Initiative

Sep 5, 2023, 7:00 AM EDT - 2 years ago

CollPlant to Present at the H.C. Wainwright Annual Growth Conference

Aug 24, 2023, 11:27 PM EDT - 2 years ago

CollPlant Biotechnologies Ltd. (CLGN) Q2 2023 Earnings Call Transcript

Aug 24, 2023, 7:00 AM EDT - 2 years ago

CollPlant Biotechnologies Announces Second Quarter Financial Results For 2023 with Revenues of $10.2 Million

Aug 9, 2023, 9:02 AM EDT - 2 years ago

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2023 SECOND QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION

prismmarketview Nov. 28 at 3:10 PM

0 · Reply

DARKP00L Nov. 28 at 2:28 PM

$CLGN 09:06 on Nov. 28 2025 D. Boral Capital Maintains Buy on CollPlant Biotechnologies, Maintains $12 Price Target #tradeideas

0 · Reply

JarvisFlow Nov. 28 at 2:06 PM

D. Boral Capital updates rating for CollPlant Biotechnologies ( $CLGN ) to Buy, target set at 12.

0 · Reply

mikesterz7 Nov. 26 at 4:23 PM

0 · Reply

StocktwitsNews Nov. 26 at 3:52 PM

0 · Reply

JarvisFlow Oct. 20 at 1:27 PM

D. Boral Capital updates rating for CollPlant Biotechnologies ( $CLGN ) to Buy, target set at 12.

0 · Reply

Tom678 Oct. 20 at 11:15 AM

$CLGN another good news

0 · Reply

Johfad54 Oct. 17 at 12:00 PM

$CLGN Someone buy this pls, need to sell

0 · Reply

Tom678 Oct. 16 at 11:24 AM

$CLGN amazing news , buying here

0 · Reply

Johfad54 Oct. 16 at 11:10 AM

$CLGN How is there only 2 people here lol

0 · Reply

SEVENXStheGOAT Oct. 16 at 11:07 AM

$CLGN First-in-Kind Fully Humanized 3D Bioprinted Human Skin Model Developed by Mayo Clinic Researchers using CollPlant's rhCollagen-Based BioInk

0 · Reply

Mfg0331 Oct. 3 at 10:42 AM

$CLGN this sht is dead wasted my time and money

0 · Reply

WhatsUpWhatsNot Oct. 2 at 7:48 PM

$AMPG and $CLGN vs $TSLA today ..no brainer..

0 · Reply

NVDAMillionaire Oct. 2 at 11:40 AM

$CLGN Really good write-up that perfectly summarizes CLGN's present situation. So if you want to bring your CLGN knowledge up to date or just discover CLGN, this is required reading. https://beyondspx.com/quote/CLGN/analysis/collplant-biotechnologies-regenerative-innovations-poised-for-market-transformation-nasdaq-clgn

0 · Reply

MichaelPremiumStocks Oct. 2 at 2:11 AM

$CLGN I srtill feel bullisn on this one

0 · Reply

WhatsUpWhatsNot Oct. 1 at 3:19 PM

$CLGN it is hard to get the full grasp,of this technology..”new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair”…time to think outside the box.

0 · Reply

Tom678 Sep. 30 at 7:57 PM

$CLGN after hour runner

0 · Reply

_www_larval_com_ Sep. 30 at 7:57 PM

$IBG -6%[39%] $UCFI 4%[-60%] $SLNH 3%[-8%] $OPAL -3%[-5%] $CLGN 3%[-10%] most notable movement into the final minutes of trading.

0 · Reply

Crazy_Gambler Sep. 30 at 6:52 PM

$CLGN Level 2 trading book has little sellers many buyers

1 · Reply

Crazy_Gambler Sep. 30 at 6:50 PM

$CLGN Some shorts got stuck and volume has dried, come and take part in the short squeeze about to occur now. $ZURA $CHOW $BURU $BENF

0 · Reply

oldwisetrader Sep. 30 at 6:44 PM

$CLGN trading above 2.90 now could see another squeeze

1 · Reply

Tom678 Sep. 30 at 6:35 PM

$CLGN

0 · Reply

Market Cap	25.68M
Revenue (ttm)	520,000.00
Net Income (ttm)	-16.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,194.23%
Debt to Equity Ratio	0.00

Volume	16,200
Avg Vol	120,690
Day's Range	N/A - N/A
Shares Out	12.78M
Stochastic %K	27%
Beta	1.43
Analysts	Strong Sell
Price Target	$11.50